Qihan Biotech Presented its Breakthrough CAR-T Research at ASGCT 2025

Qihan Biotech Presented its Breakthrough CAR-T Research at ASGCT 2025

HANGZHOU, China–(BUSINESS WIRE)–Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced new advancements in its universal CAR-T cell therapy research, to be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). Through systematic exploration of T cell cytokine…

Gene and Cell Therapies in Focus at ASGCT 2025: Tackling Rare Diseases, Autoimmune Conditions, and More

This year’s American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, held May 13–17 in New Orleans, is buzzing with new breakthroughs from the … Gene and Cell Therapies in Focus at ASGCT 2025: Tackling Rare Diseases, Autoimmune Conditions, and More Read More » The post Gene and Cell Therapies in Focus at ASGCT 2025: Tackling Rare Diseases, Autoimmune Conditions, and More first appeared on GeneOnline News. The post Gene and Cell Therapie…